
There has been a big community response to the Foundation’s campaign to allow AMD drug “switching”.
Read MoreThere has been a big community response to the Foundation’s campaign to allow AMD drug “switching”.
Read MoreThe Macular Degeneration Foundation has launched a new national awareness campaign that featured symptom recognition.
Read MoreWith a new treatment for wet AMD coming on the market, drug switching between Lucentis and Eylea should be allowed.
Read MoreResearch has revealed Australians significantly underestimate the role of family history in developing macular degeneration.
Read MoreMacular Degeneration Foundation believes a cap on the Medicare item number for the treatment of wet AMD should have minimal impact on patients.
Read MoreThe TGA has approved a new drug, Eylea, for the treatment of wet (neovascular) age-related macular degeneration.
Read MoreDame Judi Dench has revealed a diagnosis of age-related macular degeneration.
Read MoreWe reviewed the results of the CATT study, designed to compare two drugs Lucentis (ranibizumab) and Avastin (bevacizumab) used to treat wet AMD.
Read MoreThere is no compelling evidence-based research that hyperbaric oxygen treatment has a beneficial effect on AMD.
Read MoreWe aim to respond to your request by the next business day. If you require assistance sooner, please call our National Helpline on 1800 111 709 (Monday - Friday 9-5pm AEST).
If your query is about an eye emergency - including sudden changes to your vision or eye pain - please contact your optometrist or ophthalmologist as soon as possible.
Great!